Please check your internet connection and try again.
# **Atezolizumab**
## Overview
Atezolizumab is a humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). By binding to PD-L1, atezolizumab blocks its interaction with PD-1 and B7.1 receptors, thereby releasing the inhibition of T-cell immune responses.
## Primary Indications
* Non-small cell lung cancer (NSCLC) in combination with chemotherapy, or as monotherapy after platinum-based chemotherapy.
* Small cell lung cancer (SCLC) in combination with chemotherapy.
* Urothelial carcinoma in combination with chemotherapy, or as monotherapy after platinum-based chemotherapy or immunotherapy.
* Melanoma in combination with cobimetinib and vemurafenib.
## Adult Dosing
* **NSCLC:** 1200 mg intravenously (IV) every 3 weeks.
* **SCLC:** 1200 mg IV every 3 weeks in combination with carboplatin and etoposide.
* **Urothelial Carcinoma:** 1200 mg IV every 3 weeks.
* **Melanoma:** 1200 mg IV every 3 weeks in combination with cobimetinib and vemurafenib.
Infusion duration: Initial infusion over 60 minutes. Subsequent infusions over 30 minutes if tolerated.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients.
## Dose Adjustments
Dose interruptions or discontinuations may be necessary for immune-related adverse events. Refer to the full prescribing information for specific management guidelines based on toxicity severity.
## Contraindications
None specific to atezolizumab itself; however, contraindications related to combination agents must be considered.
## Adverse Effects
The most common adverse reactions include fatigue, decreased appetite, nausea, diarrhea, vomiting, rash, pyrexia, and dyspnea. Immune-related adverse events can occur in any organ system and may include pneumonitis, hepatitis, colitis, endocrinopathies (thyroid disorders, adrenal insufficiency, hypophysitis, type 1 diabetes mellitus), nephritis, and dermatologic reactions.
## Key Drug Interactions
There are no known drug interactions specific to atezolizumab. However, combination agents may have significant interactions. Caution should be exercised when administering with other immunomodulatory agents.
## Monitoring
* Monitor for signs and symptoms of immune-related adverse events.
* Regular monitoring of liver function tests, thyroid function, and renal function is recommended.
* Monitor for infusion reactions.
## Clinical Pearls
* Atezolizumab can be administered concurrently with platinum-based chemotherapy for certain indications.
* Patient education regarding potential immune-related adverse events is crucial.
* Prompt recognition and management of immune-related adverse events are essential for patient safety and to allow for continued treatment.
***
**Disclaimer:** This information is intended for healthcare professionals. Please consult the most current prescribing information and local protocols for definitive guidance.
